The FDA broadened dupilumab's (Dupixent) approval as an add-on maintenance treatment for chronic rhinosinusitis with nasal ...

In the SINUS-24 and SINUS-52 trials, Dupixent significantly improved nasal congestion/obstruction severity, nasal polyp size and sense ... with moderate-to-severe asthma and adult patients with ...

GSK’s long-acting asthma treatment has been shown to halve the number of attacks in a pair of phase 3 trials, supporting the ...

“Ninety-five percent of the cases present with severe asthma and sinus disease and nasal polyps. So, if you’re not looking ...

Depemokimab was shown to reduce exacerbations in patients with severe asthma. The proportions of adverse events of ...

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.

More than half (60%) of patients in latest trial reached active remission and 41% stopped taking corticosteroid entirely.

In a recent study investigators established that extended dupilumab therapy-up to three years-is highly effective in the ...

The Food and Drug Administration (FDA) has expanded the approval of Dupixent ® (dupilumab) to include add-on maintenance treatment of adolescent patients aged 12 to 17 years with inadequately ...

It is not known if DUPIXENT is safe and effective in children with asthma under 6 years of age. with other medicines for the maintenance treatment of chronic rhinosinusitis with nasal polyps ...

Following Priority Review, Dupixent is now available to patients as young as 12 years with inadequately controlled CRSwNPCurrent treatment ...